- Four renowned experts join to advise Bicycle as the company advances pipeline of novel cancer therapeutic candidates CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Oct. 21, 2020-- Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Oct. 14, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that preclinical data for

- ATM offering program initiated during Q3’20 fully utilized; $15.0 million drawn on debt financing facility of up to $40.0 million - Approximately $70 million generated during Q3’20 including ATM proceeds, debt financing draw and previously announced $6.7 million   UK cash R&D tax credit - Cash

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Sep. 14, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that a poster describing the

- BT8009 is the third program designed to explore the potential of Bicycles® as next-generation tumor-targeting agents - BT8009   targets Nectin-4, a well-validated tumor antigen shown to be overexpressed in several common tumor types CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Sep.

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Sep. 3, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will

- Two cohorts have been initiated: a squamous non-small cell lung cancer cohort and a solid tumor “basket” cohort; up to two additional cohorts may be added based on preliminary results - Patients will be selected using prespecified tumor membrane H-scores for MT1-MMP expression CAMBRIDGE, England

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Sep. 1, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the first patient has

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Aug. 11, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Dominic

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Aug. 5, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will